Search

Your search keyword '"Tsuji, K."' showing total 324 results

Search Constraints

Start Over You searched for: Author "Tsuji, K." Remove constraint Author: "Tsuji, K." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
324 results on '"Tsuji, K."'

Search Results

1. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

2. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

5. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

7. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

8. A fully automated novel urine cytology support artificial intelligence system for the prediction of histological high-grade urothelial carcinoma: External validation study

9. EP11.01-11 Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors

20. A1020 - A fully automated novel urine cytology support artificial intelligence system for the prediction of histological high-grade urothelial carcinoma: External validation study.

21. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

22. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.

23. An attempt to generate panoramic radiographs including jaw cysts using StyleGAN3.

24. Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma.

25. Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.

26. A case of renal hypouricemia due to T217M mutation in SLC22A12 incidentally associated with IgA nephropathy.

27. Mixed hepatocellular carcinoma and high-grade neuroendocrine neoplasm with ambiguous histopathological features: a case report.

28. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.

29. Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.

30. AnNoBrainer, An Automated Annotation of Mouse Brain Images using Deep Learning.

31. Design, synthesis and evaluation of bioactivity of peptidomimetics based on chloroalkene dipeptide isosteres.

32. ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.

33. Effects of HIF-PHD inhibitors in kidney development.

34. A novel methodology utilizing microchip implants to monitor individual activity and body temperature for assessing knee pain in group-housed rats.

35. Correction: Novel aerosol treatment of airway hyper-reactivity and inflammation in a murine model of asthma with a soluble epoxide hydrolase inhibitor.

36. A case of membranous nephropathy complicated by Cronkhite-Canada syndrome successfully treated with mizoribine.

37. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.

38. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.

39. Phase angle as an indicator of sarcopenia and malnutrition in patients with chronic obstructive pulmonary disease.

40. Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.

41. Mac-2 binding protein glycosylation isomer as a novel predictor of early recurrence after resection for hepatocellular carcinoma.

43. Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents.

44. Selective Transarterial Embolization for a Ruptured Persistent Trigeminal Artery Variant Aneurysm.

45. Development of a novel X-ray fluorescence instrument equipped with a noble gas filter.

46. A Nonlinear Photochromic Reaction Based on Sensitizer-Free Triplet-Triplet Annihilation in a Perylene-Substituted Rhodamine Spirolactam.

47. Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.

48. Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component.

49. Four new resin glycosides from Ipomoea muricata seeds: muricatins XIV-XVII.

50. RECAM-J 2023-Validation and development of the Japanese version of RECAM for the diagnosis of drug-induced liver injury.

Catalog

Books, media, physical & digital resources